

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID: ANITF240579181A

ACCESSION NO: **0181VJ001043** AGE: 43 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 22/10/2022 09:01:19 REPORTED: 27/10/2022 14:27:18

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

MEDIX WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE	Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
HEMOGLOBIN 12.2 12.0 - 15.0 9/dL	MEDT WHEEL EILLI D	ODV HEALTH CHECKID AD	OVE 40EEMALE			
HEMOGLOBIN 12.2 12.0 - 15.0 g/dL METHOD: SLS- HEMOGLOBIN DETECTION METHOD RED BLOOD CELL COUNT 4.39 3.8 - 4.8 mil/μL METHOD: ELVORDOYNAMIC FOCUSING BY DC DETECTION WHITE BLOOD CELL COUNT 8.08 4.0 - 10.0 thou/μL METHOD: ELUORESCENCE FLOW CYTOMETRY PLATELET COUNT 410 150 - 410 thou/μL METHOD: HEVORDOYNAMIC FOCUSING BY DC DETECTION RED AND PLATELET INDICES HEMATOCRIT 39.2 36.0 - 46.0 % METHOD: CAUCULATED FROM RBC & HCT MEAN CORPUSCULAR VOL 89.3 83.0 - 101.0 fl. METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. 27.8 27.0 - 32.0 pg	•		JVL 40FLMALL			
METHOD : SLS- HEMOGLOBIN DETECTION METHOD RED BLOOD CELL COUNT 4.39 3.8 - 4.8 mil/μL METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION 8.08 4.0 - 10.0 thou/μL METHOD : FLUORESCENCE FLOW CYTOMETRY 410 150 - 410 thou/μL METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION 410 150 - 410 thou/μL METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION WE FRACE AND PLATELET INDICES WE HEMATOCRIT 39.2 36.0 - 46.0 % METHOD : CUMULATIVE PUISE HEIGHT DETECTION METHOD WE WE METHOD : CALCULATED FROM RBC & HCT FRACE AND PLATELET FROM RBC & HCT WE PG MEAN CORPUSCULAR HGB. 27.8 27.0 - 32.0 pg METHOD : CALCULATED FROM THE RBC & HGB PG METHOD : CALCULATED FROM THE RBC & HGB PG METHOD : CALCULATED FROM THE RBC & HGB PG METHOD : CALCULATED FROM THE HGB & HCT PG METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT METHOD	•	A WHOLL BLOOD	12.2		12.0 - 15.0	a/dl
RED BLOOD CELL COUNT 8.39 3.8 - 4.8 mil/µL METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION WHITE BLOOD CELL COUNT 8.08 4.0 - 10.0 thou/µL METHOD : FLUORESCENCE FLOW CYTOMETRY PLATELET COUNT 410 150 - 410 thou/µL METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION METHOD : CHIVINGROPHAMIC FOR METHOD METHOD : CHIVINGROPHAMIC FORM BRC & HCT MEAN CORPUSCULAR VOL 89.3 83.0 - 101.0 fl METHOD : CALCULATED FROM BRC & HCB MEAN CORPUSCULAR HEMOGLOBIN 31.1 Low 31.5 - 34.5 g/dL METHOD : CALCULATED FROM THE HGB & HCT MENTZER INDEX RED CELL DISTRIBUTION WIDTH 12.6 11.6 - 14.0 % METHOD : CALCULATED FROM RES SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fl METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 318 Might 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES COUNT 318 Might 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES COUNT 318 Might 1.0 - 3.0 thou/µL		IN DETECTION METHOD	12.2		12.0 - 13.0	g/uL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION WHITE BLOOD CELL COUNT			4 39		38-48	mil/ul
WHITE BLOOD CELL COUNT 8.08 4.0 - 10.0 thou/µL METHOD: FLUORESCENCE FLOW CYTOMETRY PLATELET COUNT 410 150 - 410 thou/µL METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION RBC AND PLATELET INDICES HEMATOCRIT 39.2 36.0 - 46.0 % METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOL 89.3 83.0 - 101.0 fL METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. 27.8 27.0 - 32.0 pg METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN 21.6 Low 31.5 - 34.5 yg MEAN CORPUSCULAR HEMOGLOBIN 20.3 METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 20.3 MED CELL DISTRIBUTION WIDTH 12.6 12.6 11.6 - 14.0 % METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCTT WBC DIFFERENTIAL COUNT - NLR MEUTHOD: ELOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.23 2.0 - 7.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 - 90 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			1133			тт, р.
METHOD: FLUORESCENCE FLOW CYTOMETRY PLATELET COUNT METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION RBC AND PLATELET INDICES HEMATOCRIT SPECIAL STRIPPS STRIPP			8.08		4.0 - 10.0	thou/uL
RETHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION RBC AND PLATELET INDICES HEMATOCRIT 39.2 36.0 - 46.0 % METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOL 89.3 83.0 - 101.0 fL METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. 27.8 27.0 - 32.0 pg METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN 31.1 Low 31.5 - 34.5 g/dL CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 20.3 RED CELL DISTRIBUTION WIDTH 12.6 11.6 - 14.0 % METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.23 2.0 - 7.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL IGHT SCATTERING ABSOLUTE LYMPHOCYTES 039 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 Migh 1.0 - 3.0 thou/µL						, ,
RBC AND PLATELET INDICES HEMATOCRIT 39.2 36.0 - 46.0 % METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOL 89.3 83.0 - 101.0 fL METHOD : CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. 27.8 27.0 - 32.0 pg METHOD : CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN 31.1 Low 31.5 - 34.5 g/dL CONCENTRATION METHOD : CALCULATED FROM THE HGB & HCT MENTZER INDEX 20.3 RED CELL DISTRIBUTION WIDTH 12.6 11.6 - 14.0 % METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD : CALCULATED FROM PLATELET LECOUNT & PLATELET HEMATOCRIT WECO THE CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WECO THE RENTAL COUNT - NLR NEUTROPHILS 52 40 80 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 89 20 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 40 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 8 1.18 Mgh 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	PLATELET COUNT		410		150 - 410	thou/µL
HEMATOCRIT METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOL METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. METHOD: CALCULATED FROM RBC & HGB MEAN CORPUSCULAR HGB. MEAN CORPUSCULAR HGB. MEAN CORPUSCULAR HEMOGLOBIN METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX RED CELL DISTRIBUTION WIDTH METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATUCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS S2 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTES 39 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD: HYDRODYNAMIC	FOCUSING BY DC DETECTION				
METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOL 89.3 83.0 - 101.0 fL METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. 27.8 27.0 - 32.0 pg METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 20.3 RED CELL DISTRIBUTION WIDTH 12.6 11.6 - 14.0 % METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	RBC AND PLATELET	INDICES				
MEAN CORPUSCULAR VOL 89.3 83.0 - 101.0 fL METHOD : CALCULATED FROM RBC & HCT 27.8 27.0 - 32.0 pg MEAN CORPUSCULAR HGB. 27.8 27.0 - 32.0 pg METHOD : CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN 31.1 Low 31.5 - 34.5 g/dL CONCENTRATION METHOD : CALCULATED FROM THE HGB & HCT 20.3 The state of	HEMATOCRIT		39.2		36.0 - 46.0	%
METHOD : CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HGB. 27.8 27.0 - 32.0 pg METHOD : CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN 31.1 Low 31.5 - 34.5 MEAN CORPUSCULAR HEMOGLOBIN 31.1 Low 31.5 - 34.5 MEAN CONCENTRATION METHOD : CALCULATED FROM THE HGB & HCT MENTZER INDEX 20.3 RED CELL DISTRIBUTION WIDTH 12.6 11.6 - 14.0 % METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.23 2.0 - 7.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD : CUMULATIVE PUL	SE HEIGHT DETECTION METHOD				
MEAN CORPUSCULAR HGB. METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX RED CELL DISTRIBUTION WIDTH 12.6 METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCTT WBCAN PLATELET VOLUME NETHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCTT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS S2 40 - 80 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 1 3.18 High 1.0 - 3.0 thou/μL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	MEAN CORPUSCULAR \	/OL	89.3		83.0 - 101.0	fL
METHOD: CALCULATED FROM THE RBC & HGB MEAN CORPUSCULAR HEMOGLOBIN METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX RED CELL DISTRIBUTION WIDTH METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS S2 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL LIGHT SCATTERING ABSOLUTE SLOW CYTOMETRY WITH LIGHT SCATTERING METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTES 39 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD : CALCULATED FRO	OM RBC & HCT				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 20.3 RED CELL DISTRIBUTION WIDTH 12.6 METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	MEAN CORPUSCULAR H	HGB.	27.8		27.0 - 32.0	pg
CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT MENTZER INDEX 20.3 RED CELL DISTRIBUTION WIDTH 12.6 11.6 - 14.0 METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS NEUTROPHILS ABSOLUTE NEUTROPHIL COUNT 4.23 2.0 - 7.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD : CALCULATED FRO	DM THE RBC & HGB				
RED CELL DISTRIBUTION WIDTH 12.6 11.6 - 14.0 % METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.23 2.0 - 7.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	CONCENTRATION		31.1	Low	31.5 - 34.5	g/dL
MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 40 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/μL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	MENTZER INDEX		20.3			
MEAN PLATELET VOLUME 10.0 6.8 - 10.9 fL METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.23 2.0 - 7.0 thou/μL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/μL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	RED CELL DISTRIBUTION	N WIDTH	12.6		11.6 - 14.0	%
METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.23 2.0 - 7.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD : CALCULATED FRO	OM RBC SIZE DISTRIBUTION CURVE				
WBC DIFFERENTIAL COUNT - NLR NEUTROPHILS 52 40 - 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.23 2.0 - 7.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	MEAN PLATELET VOLUM	ME	10.0		6.8 - 10.9	fL
NEUTROPHILS METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING Thou cytometry with Light scattering METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD : CALCULATED FRO	DM PLATELET COUNT & PLATELET HEMAT	TOCRIT			
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING 3.18 High 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	WBC DIFFERENTIAL	COUNT - NLR				
ABSOLUTE NEUTROPHIL COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING 4.23 2.0 - 7.0 thou/µL #### 1.0 - 3.0 thou/µL	NEUTROPHILS		52		40 - 80	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES 39 20 - 40 % METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD : FLOW CYTOMETR	Y WITH LIGHT SCATTERING				
LYMPHOCYTES 39 20 - 40 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	ABSOLUTE NEUTROPHI	IL COUNT	4.23		2.0 - 7.0	thou/µL
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE LYMPHOCYTE COUNT METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING **High** 1.0 - 3.0	METHOD : FLOW CYTOMETR	Y WITH LIGHT SCATTERING				
ABSOLUTE LYMPHOCYTE COUNT 3.18 High 1.0 - 3.0 thou/µL METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	LYMPHOCYTES		39		20 - 40	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	METHOD : FLOW CYTOMETR	Y WITH LIGHT SCATTERING				
	ABSOLUTE LYMPHOCYT	TE COUNT	3.18	High	1.0 - 3.0	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.3	METHOD : FLOW CYTOMETR	Y WITH LIGHT SCATTERING				
	NEUTROPHIL LYMPHOC	CYTE RATIO (NLR)	1.3			
EOSINOPHILS 1 - 6 %	EOSINOPHILS		1		1 - 6	%



Page 1 Of 13



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE


PATIENT ID: ANITF240579181A

ACCESSION NO: **0181VJ001043** AGE: 43 Years SEX: Female ABHA NO:

RECEIVED: 22/10/2022 09:01:19 27/10/2022 14:27:18 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results	В	Biological Reference Interva	l Units
METHOD : FLOW CYTOMETR'	Y WITH LIGHT SCATTERING				
ABSOLUTE EOSINOPHI	L COUNT	0.07	0	0.02 - 0.50	thou/µL
METHOD : FLOW CYTOMETR'	Y WITH LIGHT SCATTERING				
MONOCYTES		8	2	2 - 10	%
METHOD : FLOW CYTOMETR'					
ABSOLUTE MONOCYTE		0.65	0	0.2 - 1.0	thou/µL
METHOD : FLOW CYTOMETR'					
DIFFERENTIAL COUNT	PERFORMED ON:	EDTA SMEAR			
MORPHOLOGY					
RBC		NORMOCYTIC NORMOC	CHROM	IIC	
WBC		NORMAL MORPHOLOGY	Υ		
METHOD: MICROSCOPIC EX	AMINATION				
PLATELETS		ADEQUATE			
ERYTHROCYTE SEDIN	MENTATION RATE (ESR),WI	HOLE			
E.S.R		31 H	High <	< 20	mm at 1 hr
GLYCOSYLATED HEM BLOOD	OGLOBIN(HBA1C), EDTA W	HOLE			
НВА1С		5.0	P C T A	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 ADA Guideline 2021)	%
METHOD : HPLC			•	,	
ESTIMATED AVERAGE	GLUCOSE(EAG)	96.8	<	< 116.0	mg/dL
METHOD : CALCULATED PAR	AMETER				
GLUCOSE FASTING,F	LUORIDE PLASMA				
FBS (FASTING BLOOD	SUGAR)	88	Р	Normal 75 - 99 Pre-diabetics: 100 – 125 Diabetic: > or = 126	mg/dL
METHOD : ENZYMATIC REFE	RENCE METHOD WITH HEXOKINASE				
GLUCOSE, POST-PRA	NDIAL, PLASMA				
PPBS(POST PRANDIAL	BLOOD SUGAR)	84	7	70 - 139	mg/dL
METHOD : ENZYMATIC REFE	RENCE METHOD WITH HEXOKINASE				
CORONARY RISK PRO	OFILE, SERUM				









CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID: ANITF240579181A

ACCESSION NO: **0181VJ001043** AGE: 43 Years SEX: Female ABHA NO:

RECEIVED: 22/10/2022 09:01:19 27/10/2022 14:27:18 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interval Unit
CHOLESTEROL, TOTAL	159	Desirable cholesterol level mg/dL < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240
METHOD: ENZYMATIC COLORIMETRIC ASSAY		
TRIGLYCERIDES	121	Normal: < 150 mg/dL Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500
METHOD: ENZYMATIC COLORIMETRIC ASSAY		
HDL CHOLESTEROL	55	Low HDL Cholesterol <40 mg/dL High HDL Cholesterol >/= 60
METHOD : ENZYMATIC, COLORIMETRIC		riigh ribe cholesteror 2/ = 00
CHOLESTEROL LDL	80	Adult levels: mg/dL Optimal < 100 Near optimal/above optimal: 100- 129 Borderline high : 130-159 High : 160-189 Very high : = 190
METHOD: ENZYMATIC COLORIMETRIC ASSAY		, 3
NON HDL CHOLESTEROL	104	Desirable : < 130 mg/dL Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220
CHOL/HDL RATIO	2.9	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0
LDL/HDL RATIO	1.5	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk
VERY LOW DENSITY LIPOPROTEIN	24.2	< OR = 30.0 mg/dL
LIVER FUNCTION PROFILE, SERUM		
BILIRUBIN, TOTAL METHOD: COLORIMETRIC DIAZO	0.25	Upto 1.2 mg/dL
BILIRUBIN, DIRECT	0.15	< 0.30 mg/dL
BILIRUBIN, INDIRECT	0.10	0.1 - 1.0 mg/dL



Page 3 Of 13 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID: ANITF240579181A

ABHA NO: ACCESSION NO: **0181VJ001043** AGE: 43 Years SEX: Female

RECEIVED: 22/10/2022 09:01:19 27/10/2022 14:27:18 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference	Interval Units
TOTAL PROTEIN	6.9		6.0 - 8.0	g/dL
METHOD : COLORIMETRIC	0.5		0.0 0.0	g/ uL
ALBUMIN	3.9	Low	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				<i>3,</i> ·
GLOBULIN	3.0		2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.3		1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV ABSORBANCE	15		< OR = 35	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV ABSORBANCE	12		< OR = 35	U/L
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	73		35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	10		0 - 40	U/L
LACTATE DEHYDROGENASE	160		125 - 220	U/L
METHOD: UV ABSORBANCE				
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	7		6 - 20	mg/dL
METHOD: ENZYMATIC ASSAY				
CREATININE, SERUM				
CREATININE	0.56		0.5 - 0.9	mg/dL
METHOD : COLORIMETRIC				
BUN/CREAT RATIO				
BUN/CREAT RATIO	12.50		8.0 - 15.0	
URIC ACID, SERUM				
URIC ACID	4.3		2.4 - 5.7	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY				
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	6.9		6.0 - 8.0	g/dL
METHOD : COLORIMETRIC				
ALBUMIN, SERUM				
ALBUMIN	3.9	Low	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				
GLOBULIN				
GLOBULIN	3.0		2.0 - 3.5	g/dL



Page 4 Of 13

Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156

DRAWN:

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

ABHA NO:

REPORTED:

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID: ANITF240579181A

ACCESSION NO: **0181VJ001043** AGE: 43 Years

RECEIVED: 22/10/2022 09:01:19

SEX: Female

27/10/2022 14:27:18

REFERRING DOCTOR: SELF

CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM	138	136 - 145	mmol/L
POTASSIUM	4.39	3.5 - 5.1	mmol/L
CHLORIDE	106	98 - 107	mmol/L
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
METHOD: VISUAL INSPECTION			
APPEARANCE	CLEAR		
METHOD: VISUAL INSPECTION			
SPECIFIC GRAVITY	1.005	1.003 - 1.035	
METHOD: IONIC CONCENTRATION METHOD			
CHEMICAL EXAMINATION, URINE			
PH	6.0	4.7 - 7.5	
METHOD: DOUBLE INDICATOR PRINCIPLE			
PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID			
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD: GLUCOSE OXIDASE PEROXIDASE			
KETONES	NOT DETECTED	NOT DETECTED	
METHOD: NITROPRUSSIDE REACTION			
BLOOD	NOT DETECTED	NOT DETECTED	
METHOD : PEROXIDASE	NORMAL	NORMAL	
UROBILINOGEN	NORMAL	NORMAL	
METHOD: MODIFIED EHRLICH REACTION NITRITE	NOT DETECTED	NOT DETECTED	
METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE	NOT DETECTED	NOT BETECTED	
	2-3	0-5	/HPF
PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION	2-3	0-3	/HPF
EPITHELIAL CELLS	1-2	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION	1 4	0 3	/ 1 11 1
ERYTHROCYTES (RBC'S)	NOT DETECTED	NOT DETECTED	/HPF
METHOD: MICROSCOPIC EXAMINATION			,
CASTS	NOT DETECTED		



Page 5 Of 13 Scan to View Report



ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MÈHRAULI SOUTH WEST DELHI

NEW DELHT 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

ANITF240579181A

ACCESSION NO: 0181VJ001043

REFERRING DOCTOR: SELF

AGE: 43 Years

SEX · Female

ABHA NO: REPORTED:

27/10/2022 14:27:18

DRAWN:

RECEIVED: 22/10/2022 09:01:19

CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final** METHOD: MICROSCOPIC EXAMINATION

CRYSTALS

NOT DETECTED

BACTERIA

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED

NOT DETECTED

THYROID PANEL, SERUM 114.0

80 - 200

ng/dL

YFAST

METHOD: ELECTROCHEMILUMINESCENCE

10.00

5.1 - 14.1

μg/dL

T4

METHOD: ELECTROCHEMILUMINESCENCE

1.820

0.27 - 4.2

μIU/mL

METHOD: ELECTROCHEMILUMINESCENCE

PAPANICOLAOU SMEAR

TSH 3RD GENERATION

TEST METHOD

CONVENTIONAL GYNEC CYTOLOGY

METHOD: MICROSCOPIC EXAMINATION

SPECIMEN TYPE

P-1238/22

TWO UNSTAINED CERVICAL SMEARS RECEIVED

METHOD: MICROSCOPIC EXAMINATION

REPORTING SYSTEM SPECIMEN ADEQUACY 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SATISFACTORY

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

MICROSCOPY

THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW INTERMEDIATE SQUAMOUS CELLS, MANY CLUSTERS OF ENDOCERVICAL

METHOD: PAP STAIN

INTERPRETATION / RESULT

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

CELLS IN THE BACKGROUND OF MODERATE POLYMORPHS.

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

Comments

PLEASE NOTE PAPANICOLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVED FOR 5 YEARS ONLY.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: GEL COLUMN AGGLUTINATION METHOD.



Page 6 Of 13 Scan to View Report



ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MÈHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID: ANITF240579181A

ACCESSION NO: 0181VJ001043 AGE: 43 Years SEX · Female ABHA NO:

RECEIVED: 22/10/2022 09:01:19 27/10/2022 14:27:18 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval **Test Report Status** Units **Final**

RH TYPE POSITIVE

METHOD: GEL COLUMN AGGLUTINATION METHOD.

XRAY-CHEST

NO ABNORMALITY DETECTED **IMPRESSION**

TMT OR ECHO

TMT OR ECHO **NEGATIVE**

ECG

ECG WITHIN NORMAL LIMITS

MAMOGRAPHY (BOTH BREASTS)

MAMOGRAPHY BOTH BREASTS SONOMAMMOGRAPHY: - SIMPLE CYST IN RIGHT BREAST.

MEDICAL HISTORY

RELEVANT PRESENT HISTORY **NOT SIGNIFICANT** RELEVANT PAST HISTORY **NOT SIGNIFICANT**

RELEVANT PERSONAL HISTORY MARRIED / 2 CHILD / MIXED DIET / CURD- ALLERGIES / NO SMOKING /

NO ALCOHOL.

RELEVANT FAMILY HISTORY FATHER:-DIABETES. HISTORY OF MEDICATIONS **NOT SIGNIFICANT**

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.60 mts WEIGHT IN KGS. 78 Kgs

BMI 30 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE **NORMAL** GENERAL APPEARANCE / NUTRITIONAL STATUS **OBESE BUILT / SKELETAL FRAMEWORK AVERAGE** FACIAL APPEARANCE NORMAL SKIN NORMAL UPPER LIMB **NORMAL** LOWER LIMB **NORMAL NECK NORMAL**



Page 7 Of 13 Scan to View Report



ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MÈHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID:

ANITF240579181A

AGE: 43 Years SEX · Female

ABHA NO:

DRAWN:

RECEIVED: 22/10/2022 09:01:19

REPORTED:

27/10/2022 14:27:18

REFERRING DOCTOR: SELF

Test Report Status

ACCESSION NO: 0181VJ001043

CLIENT PATIENT ID:

Units

Results

Biological Reference Interval

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

Final

THYROID GLAND NOT ENLARGED

BREAST (FOR FEMALES) NORMAL TEMPERATURE NORMAL

PULSE 88/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

130/80 MM HG BP mm/Hg

(SUPINE)

PERICARDIUM NORMAL APEX BEAT **NORMAL HEART SOUNDS NORMAL MURMURS ABSENT**

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST **NORMAL** MOVEMENTS OF CHEST **SYMMETRICAL BREATH SOUNDS INTENSITY NORMAL**

VESICULAR (NORMAL) **BREATH SOUNDS QUALITY**

ADDED SOUNDS **ABSENT**

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE ABSENT

LIVER **NOT PALPABLE SPLEEN NOT PALPABLE ABSENT**

HERNIA

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS **NORMAL** SENSORY SYSTEM **NORMAL** MOTOR SYSTEM **NORMAL REFLEXES NORMAL**

MUSCULOSKELETAL SYSTEM



Page 8 Of 13 Scan to View Report



ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

2)ANNUAL SONOMAMMOGRPAHY TO MONITOR BREAST CYST.

3) GYNAEC CONSULT FOR UTERINE FIBROIDS.

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID: ANITF240579181A

ACCESSION NO: **0181VJ001043** AGE: 43 Years SEX: Female ABHA NO:

27/10/2022 14:27:18 RECEIVED: 22/10/2022 09:01:19 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

REFERRING DOCTOR:	SLLF	CLIENT FATIENT ID .				
Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units		
SPINE		NORMAL				
JOINTS		NORMAL				
BASIC EYE EXAMINA	ATION					
CONJUNCTIVA		NORMAL				
EYELIDS		NORMAL				
EYE MOVEMENTS		NORMAL				
CORNEA		NORMAL				
DISTANT VISION RIGH	HT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT				
DISTANT VISION LEFT	EYE WITHOUT GLASSES	REDUCED VISUAL ACUITY 6/9				
DISTANT VISION RIGH	HT EYE WITH GLASSES	WITH GLASSES NORMAL				
DISTANT VISION LEFT	EYE WITH GLASSES	WITH GLASSES NORMAL				
NEAR VISION RIGHT EYE WITHOUT GLASSES		WITHIN NORMAL LIMIT				
NEAR VISION LEFT EY	E WITHOUT GLASSES	WITHIN NORMAL LIMIT				
COLOUR VISION		NORMAL				
SUMMARY						
RELEVANT HISTORY		NOT SIGNIFICANT				
RELEVANT GP EXAMIN	ATION FINDINGS	OBESE ;- BMI 30				
REMARKS / RECOMME	NDATIONS	ADVICE:- 1)WEIGHT LOSS:- LOW C EXERCISE.	CALORIE, HIGH FIBRE DIET, REGULA	.R		





Page 9 Of 13



CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MÈHRAULI SOUTH WEST DELHI

NEW DELHT 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

ARHA NO ·

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID:

ANITF240579181A

AGE: 43 Years

DRAWN:

RECEIVED: 22/10/2022 09:01:19

SEX · Female

REPORTED:

27/10/2022 14:27:18

REFERRING DOCTOR: SELF

Test Report Status

ACCESSION NO: 0181VJ001043

Results

CLIENT PATIENT ID:

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

GRADE I FATTY LIVER

BULKY UTERUS WITH UTERINE FIBROIDS.

Final

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. WBC DIFFERENTIAL COUNT-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION**:
Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall

(sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis) In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.

3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.



Page 10 Of 13

Scan to View Report



CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MÈHRAULI SOUTH WEST DELHI

ACCESSION NO: 0181VJ001043

NEW DELHT 110030 **DELHI INDIA** 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID:

ANITF240579181A

AGE: 43 Years SEX · Female

ARHA NO ·

DRAWN:

RECEIVED: 22/10/2022 09:01:19

27/10/2022 14:27:18 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin,

ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and< 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
 Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
 Muscular dystrophy URIC ACID, SERUM-

Causes of Increased levels



Page 11 Of 13 Scan to View Report



CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MÈHRAULI SOUTH WEST DELHI NEW DELHT 110030

DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID: ANITF240579181A

AGE: 43 Years SEX · Female ACCESSION NO: 0181VJ001043 ABHA NO:

27/10/2022 14:27:18 DRAWN: RECEIVED: 22/10/2022 09:01:19 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

- Dietary
 High Protein Intake.
- Prolonged Fasting,
- Rapid weight loss.

Gout

Lesch nyhan syndrome.

Type 2 DM.

Metabolic syndrome

Causes of decreased levels

- Low Zinc Intake
- OCP's
- Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluids
- Limit animal proteins
- High Fibre foods
- Vit C IntakeAntioxidant rich foods

TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

ELECTROLYTES (NA/K/CL), SERUMSodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting,
MICROSCOPIC EXAMINATION, URINE-

Routine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders

Protein: Elevated proteins can be an early sign of kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever

Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain medications.

Ketones: Uncontrolled diabetes mellitus can lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous

Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders.

Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.

Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retained in bladder prior to collection.
pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food

can affect the pH of urine.

Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus.

Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine.

Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia

THYROID PANEL, SERUM-Triiodothyronine T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.



Page 12 Of 13 Scan to View Report



CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MÈHRAULI

SOUTH WEST DELHI **NEW DELHT 110030 DELHI INDIA**

8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ANITA ANIL SALUNKHE

PATIENT ID: ANITF240579181A

AGE: 43 Years SEX · Female ACCESSION NO: 0181VJ001043 ABHA NO:

27/10/2022 14:27:18 DRAWN: RECEIVED: 22/10/2022 09:01:19 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3

Levels in TOTAL T4 TSH3G TOTAL T3 (µg/dL) (µIU/mL) (ng/dL) Pregnancy 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 First Trimester 2nd Trimester 6.6 - 12.4 6.6 - 15.5 81 - 190 100 - 260 3rd Trimester 6.6 - 15.5 100 - 260

Below mentioned are the guidelines for age related reference ranges for T3 and T4.

T3

T4

(µg/dL) 1-3 day: 8.2 - 19.9 (ng/dL) New Born: 75 - 260 1 Week: 6.0 - 15.9

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing on the report under biological reference range.

Reference:

- Reference:

 1. Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.

 2. Gowenlock A.H. Varley'''s Practical Clinical Biochemistry, 6th Edition.

 3. Behrman R.E. Kilegman R.M., Jenson H. B. Nelson Text Book of Pediatrics, 17th Edition

 ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession



Page 13 Of 13

Scan to View Report